How can I safely taper alprazolam 0.25 mg taken at bedtime in a patient who has used it for many years and is now experiencing insomnia, and how should mirtazapine be introduced to help with sleep?

Tapering Alprazolam and Introducing Mirtazapine for Chronic Insomnia

For a patient on long-term alprazolam 0.25 mg at bedtime, taper by reducing the dose by 10-25% weekly (approximately 0.025-0.0625 mg per week), and introduce mirtazapine 15 mg at bedtime concurrently at the start of the taper to address insomnia and potentially ease withdrawal symptoms. 1, 2

Alprazolam Tapering Strategy

The key principle is hyperbolic (proportionate) tapering rather than linear tapering. Linear reductions produce increasingly large changes in GABA-A receptor occupancy as the dose decreases, causing escalating withdrawal symptoms. 3 For your patient on 0.25 mg:

• Start with 10-25% weekly reductions (0.025-0.0625 mg per week) 2
• After long-term use (many years), expect the taper to take several months
• As you approach very low doses (below 0.125 mg), you may need to slow the taper further
• Final doses may need to be as small as 0.025 mg or less before complete discontinuation 3
• Consider using liquid formulations or compounded preparations to achieve these tiny dose reductions 3

Critical Withdrawal Considerations

Alprazolam withdrawal can cause rebound insomnia of comparable magnitude to the original improvement seen with the drug. 4 The FDA label warns that abrupt discontinuation causes serious withdrawal effects including seizures. 5 Reduce by no more than 0.5 mg every 3 days per FDA guidance, but given your patient's low dose and long-term use, the slower 10-25% weekly reduction is more appropriate. 5, 2

Mirtazapine Introduction

Start mirtazapine 15 mg at bedtime immediately when beginning the alprazolam taper. 1 This serves multiple purposes:

• Addresses the underlying insomnia with a non-benzodiazepine agent
• May help alleviate withdrawal symptoms during the taper 6
• The FDA label explicitly states mirtazapine should be taken "preferably in the evening prior to sleep" 1
• Recent evidence shows ultra-low doses (3.75 mg) can improve insomnia, but start with the FDA-recommended 15 mg dose and adjust based on response 1, 7

Mirtazapine Dosing Details

• If 15 mg is insufficient after 1-2 weeks, increase up to 45 mg maximum 1
• Do not make dose changes more frequently than every 1-2 weeks 1
• The sedating effect is actually stronger at lower doses (15 mg) due to antihistamine effects; higher doses may be less sedating but more antidepressant

Critical Drug Interaction Warning

The FDA label explicitly warns to avoid benzodiazepines during mirtazapine treatment. 1 However, in the context of a supervised taper, the overlapping period is necessary and acceptable with close monitoring. Warn the patient about:

• Enhanced sedation and drowsiness
• Impaired driving ability
• Avoid alcohol completely 1
• Risk of respiratory depression, especially if other CNS depressants are present

Augment with Cognitive Behavioral Therapy

Strongly recommend concurrent CBT for insomnia (CBT-I) during the taper. The evidence shows CBT-I plus gradual tapering is significantly more effective than tapering alone (RR: 1.68,95% CI: 1.19-2.39). 8 This improves both benzodiazepine discontinuation rates and insomnia symptoms. 8

Recent high-quality evidence shows that masked tapering combined with augmented CBT-I (targeting placebo mechanisms) achieved 73.4% discontinuation at 6 months versus 58.6% with standard unmasked taper. 9

Monitoring and Adjustment

Watch for these specific withdrawal symptoms:

• Insomnia worsening (rebound insomnia is expected) 5, 4
• Anxiety, irritability, confusion 5
• Seizures (rare but serious) 5
• Muscle twitching, tremor 5

If withdrawal symptoms become intolerable, slow the taper rate or hold at the current dose for 1-2 weeks before resuming. 2 The taper should be adjusted based on symptom severity, not a rigid schedule.

Why Not Other Alternatives

Guidelines explicitly recommend against benzodiazepines for chronic insomnia due to dependency risk, falls, cognitive impairment, and respiratory depression that substantially outweigh benefits. 10 Your patient exemplifies this problem—years of use with persistent insomnia.

Trazodone was considered but guidelines advise against it due to low-quality efficacy evidence and adverse effects. 10 Antihistamines develop tolerance after 3-4 days and are strongly contraindicated in older adults per Beers Criteria. 10

Practical Implementation

1. Week 1: Start mirtazapine 15 mg at bedtime, reduce alprazolam to 0.225 mg (10% reduction)
2. Week 2-8: Continue reducing alprazolam by 0.025 mg weekly
3. Week 9+: As dose drops below 0.1 mg, consider even slower reductions (0.0125 mg every 1-2 weeks)
4. Throughout: Monitor for withdrawal symptoms and adjust taper speed accordingly
5. Final step: The last reduction from 0.025 mg to zero should not feel larger than previous reductions

The entire process will likely take 3-6 months or longer depending on tolerance of withdrawal symptoms. 2, 3